Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Charles J. Ryan, Dana E. Rathkopf, Cora N. Sternberg et al.|The Lancet Oncology|2015

Cited by 1.4k